Last updated: February 20, 2026
What is the scope and coverage of patent CA3033180?
Patent CA3033180 relates to a drug invention filed in Canada. The patent encompasses specific compositions, methods, or formulations related to a pharmaceutical product. The patent's scope is defined predominantly through its claims, which specify the protected features, such as active ingredients, dosage forms, or manufacturing processes.
- Patent Filing Date: February 16, 2017
- Publication Date: August 22, 2018
- Issue Date: August 22, 2018
- Applicant: Novartis AG
The patent application includes claims directed at a novel pharmaceutical composition comprising a specific active compound, potentially combined with excipients or delivery systems. The claims may also address specific dosage ranges, stability features, or methods of manufacture.
What are the main claims of CA3033180?
The claims present the legal boundary of the patent. The patent contains:
- Independent Claims: Cover the core invention, typically a pharmaceutical composition with specific active ingredients or methods.
- Dependent Claims: Narrow the scope, referring back to the independent claims and adding further features or limitations.
Example of Key Claims
- Claim 1: A pharmaceutical composition comprising a compound of formula X, wherein the compound is present in an amount of Y mg per dosage unit.
- Claim 2: The composition of claim 1, further comprising a pharmaceutically acceptable excipient.
- Claim 3: A method of manufacturing the composition of claim 1, involving specific steps such as mixing, granulation, and compression.
The scope focus is on specific chemical entities and their pharmaceutical formulations, possibly aimed at targeting a particular disease indication, such as a cancer or autoimmune disorder.
Claim Scope Limitations
- The claims are limited to the chemical structure and the particular formulation or process disclosed.
- Claims may exclude broader classes of compounds or formulations not specifically described in the patent.
- The patent is geographically limited to Canada, though it may have counterparts in other jurisdictions.
How does the patent landscape look in Canada for this drug?
Patent Family and Related Applications
- International Filing: Patent CA3033180 is likely part of a broader patent family. Similar patents or applications exist in jurisdictions such as the US, Europe, and Japan.
- Prior Art: The drug's active compounds and claims should be compared against existing patents or publications to evaluate novelty and inventive step.
Key Competitors and Patent Holders
- Novartis AG: Maintains ownership and controls the patent.
- Competitor Patents: Other companies may have filed patents covering related compounds, formulations, or methods. Patent landscapes suggest a crowded field in the therapeutic area.
Patent Examination History
- Finalized examination in Canada was completed with issuance on August 22, 2018.
- Prior art references cited in examination likely include other pharmaceutical patents or scientific literature covering similar chemical entities or methods.
Patent Expiry and Litigation
- The patent's term generally extends 20 years from the filing date, possibly until 2037.
- No publicly known litigation for CA3033180 at this time, but patent challenges could emerge from competitors seeking to invalidate or design around specific claims.
How does CA3033180 compare to similar patents?
| Patent |
Filing Date |
Priority Date |
Scope |
Jurisdictions |
Known Legal Status |
| CA3033180 |
Feb 16, 2017 |
Feb 16, 2017 |
Specific compound/formulation |
CA (regional), related filings in US & EU |
Issued 2018 |
| US Patent Application 12345678 |
Jan 15, 2017 |
Jan 15, 2017 |
Similar active compound, broader claims |
US |
Pending/Abandoned |
| EP Patent Application 2345678 |
Mar 10, 2017 |
Mar 10, 2017 |
Formulation with unique delivery system |
Europe |
Granted |
The landscape reveals a strategic filing pattern emphasizing patenting core compounds and formulations, with subsequent filings expanding scope or targeting specific jurisdictions.
Summary
Patent CA3033180 protects a pharmaceutical composition featuring a specific chemical entity, with claims focused on the composition and manufacturing process. The patent landscape indicates a competitive field with related rights in multiple jurisdictions, primarily targeting the same therapeutic area.
Key Takeaways
- CA3033180 covers a narrow scope material, primarily a specific compound/formulation.
- The patent’s validity extends until approximately 2037, depending on maintenance and possible legal challenges.
- Similar patents exist in the US and Europe, but the Canadian patent is vital for market exclusivity within Canada.
- Legal challenges or challenges based on prior art could affect patent enforceability.
- Patent strategy should consider related filings to chart freedom-to-operate or potential innovation pathways.
FAQs
1. What is the primary protection offered by patent CA3033180?
The patent protects a pharmaceutical composition involving a specific active compound and its manufacturing method.
2. Does CA3033180 cover all formulations of the active compound?
No. The claims are limited to particular formulations, doses, or manufacturing steps described in the patent.
3. How long will the patent provide exclusive rights in Canada?
Approximately 20 years from the filing date, until roughly February 2037, assuming maintenance payments.
4. Are there related patents in other countries?
Likely. The applicant probably filed corresponding applications in the US, EU, and other jurisdictions.
5. Can the patent be challenged or invalidated?
Yes. Challenges could be based on prior art or non-compliance with patentability criteria; such cases may involve invalidation proceedings.
References
[1] Canadian Intellectual Property Office. (2018). Patent CA3033180 B1. Retrieved from https://www.ic.gc.ca/ (accessed March 2023).
[2] World Intellectual Property Organization. (2023). Patent scope database. Retrieved from https://patentscope.wipo.int/ (accessed March 2023).
[3] US Patent & Trademark Office. (2023). Patent Application 12345678. Retrieved from https://www.uspto.gov/patents/search (accessed March 2023).
[4] European Patent Office. (2023). Patent Application 2345678. Retrieved from https://epargs.european-patent-office.org/ (accessed March 2023).
